CN113521248A - Application of probiotic active peptide in preparation of medicine, food or health-care product with effect of preventing or treating diarrhea - Google Patents
Application of probiotic active peptide in preparation of medicine, food or health-care product with effect of preventing or treating diarrhea Download PDFInfo
- Publication number
- CN113521248A CN113521248A CN202111032263.7A CN202111032263A CN113521248A CN 113521248 A CN113521248 A CN 113521248A CN 202111032263 A CN202111032263 A CN 202111032263A CN 113521248 A CN113521248 A CN 113521248A
- Authority
- CN
- China
- Prior art keywords
- formula
- active peptide
- probiotic active
- diarrhea
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 63
- 239000006041 probiotic Substances 0.000 title claims abstract description 62
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 62
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 62
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 235000013305 food Nutrition 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 241000702670 Rotavirus Species 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 206010051511 Viral diarrhoea Diseases 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 241000700605 Viruses Species 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to the technical field of biomedicine, and particularly discloses application of probiotic active peptide in preparation of a medicament, food or health-care product with a function of preventing or treating diarrhea. The probiotic active peptide has a structure shown in a formula I or a formula II. The probiotic active peptide composition comprises probiotic active peptides with structures shown in a formula I and a formula II. The research shows that: the probiotic active peptide with the structures shown in the formula I and the formula II has the effect of resisting diarrhea, in particular to the effect of resisting virus diarrhea caused by rotavirus; therefore, the skilled person can use the compound as an active ingredient for preparing a medicament, food or health-care product with the effect of preventing or treating diarrhea.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to application of probiotic active peptide in preparation of a medicament, food or health-care product with a function of preventing or treating diarrhea.
Background
Viral diarrhea is a group of acute gastrointestinal infectious diseases caused by viruses, and is clinically characterized by acute onset, nausea, vomiting, abdominal pain, diarrhea (watery stool or loose stool), fever, general malaise and other symptoms. Among them, there are many types of viruses involved in acute gastroenteritis, among which rotavirus and norovirus are more important and studied. Therefore, the screening of the small molecular compound with the biological activity of resisting viral diarrhea has important application value.
The inventor of the invention develops a brand-new probiotic active peptide with structures shown in formula I and formula II in previous researches, and applies for Chinese invention patent 202110124497.8, wherein the publication date of the patent is 2021, 5 and 18 days, and the publication number is CN 112812150A. However, the Chinese patent 202110124497.8 only discloses that the probiotic active peptide with the structure shown in formula I and formula II has the effect of resisting skin cell oxidation and/or inflammatory injury caused by UV; it is not mentioned that the probiotic active peptide with the structure shown in formula I and formula II has antiviral diarrhea effect.
Disclosure of Invention
The method is based on the insufficient development of the existing anti-diarrhea drugs, in particular to the insufficient development of the anti-viral diarrhea drugs; the invention provides application of probiotic active peptide in preparation of medicines, foods or health-care products with diarrhea treatment effect.
The detailed technical scheme of the invention is as follows:
the application of probiotic active peptide in preparing medicines, foods or health products with the effect of preventing or treating diarrhea is disclosed, wherein the probiotic active peptide has a structure shown in a formula I or a formula II:
the probiotic active peptides with the structures shown in the formula I and the formula II are two probiotic active peptides prepared by the inventor in previous researches, and the preparation method is disclosed in the publication with the publication number of CN 112812150A. The inventor surprisingly found that the probiotic active peptide with the structures shown in the formula I and the formula II has the effect of resisting diarrhea, particularly the effect of resisting virus diarrhea caused by rotavirus. Therefore, the skilled person can use the compound as an active ingredient for preparing a medicament, food or health-care product with the effect of preventing or treating diarrhea.
Preferably, the diarrhea is viral diarrhea.
Preferably, the viral diarrhea is rotavirus-induced viral diarrhea.
The invention also provides application of the probiotic active peptide composition in preparation of medicines, foods or health products with the effect of preventing or treating diarrhea, wherein the probiotic active peptide composition comprises probiotic active peptides with structures shown in a formula I and a formula II.
Preferably, the mass ratio of the probiotic active peptide with the structure shown in the formula I to the probiotic active peptide with the structure shown in the formula II is 1-8: 1-8.
Further preferably, the mass ratio of the probiotic active peptide with the structure shown in the formula I to the probiotic active peptide with the structure shown in the formula II is 1-4: 1-4.
Most preferably, the mass ratio of the probiotic active peptide with the structures shown in the formula I and the formula II is 1: 1.
The inventor further surprises the discovery in further research: after the probiotic active peptides with the structures shown in the formula I and the formula II are combined, the effect of resisting rotavirus diarrhea is better than that of singly using the probiotic active peptide with the structure shown in the formula I or singly using the probiotic active peptide with the structure shown in the formula II; the results show that the probiotic active peptide with the structures shown in the formula I and the formula II can play a role in synergistically resisting the viral diarrhea caused by rotavirus after being combined. Therefore, the probiotic active peptides with the structures shown in the formula I and the formula II can be combined by the technicians in the field to be used as active ingredients for developing medicaments, foods or health-care products with better effect and the effect of preventing or treating diarrhea. Or in the development of medicaments, foods or health-care products with the effect of preventing or treating diarrhea, the combination of the probiotic active peptides with the structures shown in the formula I and the formula II is adopted, so that the same effect can be achieved by using a small amount of the probiotic active peptides with the structures shown in the formula I and the formula II; thereby reducing the dosage of active ingredients and saving the production cost.
Preferably, the diarrhea is viral diarrhea.
Preferably, the viral diarrhea is rotavirus-induced viral diarrhea.
The medicine, food or health product of the invention can be prepared by the conventional technical means in the field by the technical personnel in the field.
The medicine, food or health care product takes the probiotic active peptide with the structure shown in the formula I or the formula II or the probiotic active peptide composition with the structure shown in the formula I and the formula II as an active ingredient, and can also comprise a carrier.
Optionally, the carrier comprises at least one of a solvent, a polymer, and a liposome. Still further optionally, the solvent includes, but is not limited to, water, physiological saline, and other non-aqueous solvents.
Specifically, the polymer may be, but is not limited to, polylysine, polyethyleneimine and modifications thereof, chitosan, polylactic acid, gelatin.
In particular, the liposome may be, but is not limited to, cholesterol, soy lecithin, egg yolk lecithin.
Further optionally, the carrier further comprises one or more of a diluent and an excipient.
Specifically, the diluent includes one or more of starches, sugars, celluloses and inorganic salts.
Specifically, the excipient comprises at least one of a binder, a filler, a lubricant in a tablet, a matrix part in a semisolid preparation ointment or cream, a preservative in a liquid preparation, an antioxidant, a flavoring agent, an aromatic agent, a cosolvent, an emulsifier and a coloring agent.
Optionally, the mass fraction of the probiotic active peptide with the structure shown in formula I or formula II or the probiotic active peptide composition with the structure shown in formula I and formula II is 10% -60%.
Further optionally, the mass fraction of the probiotic active peptide with the structure shown in formula I or formula II or the probiotic active peptide composition with the structure shown in formula I and formula II is 5% -30%, 15% -40% or 25% -60%.
Optionally, the pharmaceutical, food or health product may further comprise a second active ingredient. The second active ingredient is selected according to the use of the composition and is not limited herein.
Specifically, including but not limited to, when the composition is used for antiviral diarrhea, the second active ingredient has antiviral diarrhea activity.
Specifically, the second active ingredient includes at least one of vitamin C, vitamin E, coenzyme Q, glutathione, carotene, and betaine.
Further optionally, the mass fraction of the second active ingredient in the composition is 1% -60%.
Alternatively, the form of the pharmaceutical, food or nutraceutical comprises a tablet, a capsule, a powder, a granule, a pill, a syrup, a solution, a suspension or an aerosol.
Optionally, the drug is at least one of a chemical drug and a biological drug. Further optionally, the biological drug is one or more of a polypeptide drug, a protein drug and a gene drug.
Optionally, the health product also comprises a gel or aqueous agent.
Further optionally, the health product further comprises an auxiliary material matrix, wherein the auxiliary material matrix comprises monosaccharide, oligosaccharide, polysaccharide, amino acid, preservative, pH regulator and anti-inflammatory auxiliary agent.
Has the advantages that: the invention provides the probiotic active peptide with the structures shown in the formula I and the formula II for the first time, which has the function of resisting diarrhea, in particular to the function of resisting viral diarrhea caused by rotavirus; therefore, the skilled person can use the compound as an active ingredient for preparing a medicament, food or health-care product with the effect of preventing or treating diarrhea. Further studies have shown that: after the probiotic active peptides with the structures shown in the formula I and the formula II are combined, the effect of resisting rotavirus diarrhea is better than that of singly using the probiotic active peptide with the structure shown in the formula I or singly using the probiotic active peptide with the structure shown in the formula II; the results show that the probiotic active peptide with the structures shown in the formula I and the formula II can play a role in synergistically resisting the viral diarrhea caused by rotavirus after being combined. Therefore, the probiotic active peptides with the structures shown in the formula I and the formula II can be combined by the technicians in the field to be used as active ingredients for developing medicaments, foods or health-care products with better effect and the effect of preventing or treating diarrhea.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only drawings of some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
For better reference, the probiotic active peptide with the structure shown in the formula I is abbreviated as LRCP-1, the probiotic active peptide with the structure shown in the formula II is abbreviated as LRCP-2, and the composition consisting of the probiotic active peptides with the structures shown in the formula I and the formula II is abbreviated as LRCP-T.
FIG. 1 is a graph of LRCP-1, LRCP-2 and their combination LRCP-T inhibiting rotavirus infected mouse inflammatory cytokine secretion.
FIG. 2 is a graph showing that LRCP-1, LRCP-2 and their combination LRCP-T inhibit the secretion of NO and PGE2 and the expression of iNOS and COX-2 in small intestine epithelial cells of mice infected by rotavirus.
FIG. 3 is a graph showing that LRCP-1, LRCP-2 and their combination LRCP-T inhibit small intestine epithelial cell NF-kB and NLRP3 inflammasome activation caused by rotavirus infection of mice.
Detailed Description
The technical solution of the present invention will be clearly and completely described with reference to the following examples. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In order to evaluate the antiviral diarrhea effect of the composition (LRCP-T; which is composed of the probiotic active peptides with the structures shown in the formula I and the formula II according to the mass ratio of 1: 1) consisting of the probiotic active peptide with the structure shown in the formula I (LRCP-1 for short), the probiotic active peptide with the structure shown in the formula II (LRCP-2 for short) and the probiotic active peptides with the structures shown in the formula I and the formula II (LRCP-T for short), the following experiments are carried out.
2 days old mice were inoculated with 30 μ L of rotavirus infected MA-104 cells by oral gavage. 2 days after inoculation (DPI 2), mice were observed for diarrheal symptoms and given the following medication groups:
a blank control group;
② rotavirus group (virus inoculation and physiological saline administration);
LRCP-1 group: inoculating virus, and dissolving and intragastrically administering 1mg/kg/d LRCP-1 with 200 μ L physiological saline;
LRCP-2 group: inoculating virus, and dissolving and intragastrically administering 1mg/kg/d LRCP-2 with 200 μ L physiological saline;
LRCP-T group: inoculating the virus, and dissolving and intragastrically in 200 mu L of physiological saline, wherein the LRCP-T is 1 mg/kg/d;
DPI 7 mice were sacrificed and relevant indices were examined.
The experimental results are as follows:
the study finds that LRCP-1, LRCP-2 and LRCP-T have certain inhibition effect on inflammatory cytokine secretion caused by virus infection (as shown in figure 1). Wherein, under the same concentration condition, the LRCP-T has stronger inhibition effect on the secretion of inflammatory cytokines caused by virus infection than LRCP-1 and LRCP-2. In addition, LRCP-1, LRCP-2 and LRCP-T all have certain inhibitory action on NO and PGE2 secretion of small intestine epithelial cells and iNOS and COX-2 expression caused by virus infection (as shown in FIG. 2). Further studies showed that the inhibition of viral infection by LRCP-1, LRCP-2 and LRCP-T could result in intestinal cell damage by modulating NF-. kappa.B and NLRP3 inflammasome (as shown in FIG. 3). In addition, the action activity of LRCP-T is stronger than that of LRCP-1 and LRCP-2, probably because of the synergistic effect between LRCP-1 and LRCP-2.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Claims (9)
1. The application of probiotic active peptide in preparing medicines, foods or health products with the effect of preventing or treating diarrhea is characterized in that the probiotic active peptide has a structure shown in a formula I or a formula II:
2. the use of claim 1, wherein the diarrhea is viral diarrhea.
3. The use of claim 2, wherein the viral diarrhea is rotavirus-induced viral diarrhea.
4. The application of a probiotic active peptide composition in the preparation of medicines, foods or health products with the effect of preventing or treating diarrhea is characterized in that the probiotic active peptide composition comprises probiotic active peptides with structures shown in a formula I and a formula II.
5. The use of claim 4, wherein the mass ratio of the probiotic active peptide with the structure shown in formula I to the probiotic active peptide with the structure shown in formula II is 1-8: 1-8.
6. The use of claim 4, wherein the mass ratio of the probiotic active peptide with the structure shown in formula I to the probiotic active peptide with the structure shown in formula II is 1-4: 1-4.
7. The use of claim 4, wherein the ratio of the mass of the probiotic active peptides having the structure represented by formula I to the mass of the probiotic active peptides having the structure represented by formula II is 1: 1.
8. The use of claim 4, wherein the diarrhea is viral diarrhea.
9. The use of claim 8, wherein the viral diarrhea is rotavirus-induced viral diarrhea.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111032263.7A CN113521248A (en) | 2021-09-03 | 2021-09-03 | Application of probiotic active peptide in preparation of medicine, food or health-care product with effect of preventing or treating diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111032263.7A CN113521248A (en) | 2021-09-03 | 2021-09-03 | Application of probiotic active peptide in preparation of medicine, food or health-care product with effect of preventing or treating diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113521248A true CN113521248A (en) | 2021-10-22 |
Family
ID=78092412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111032263.7A Pending CN113521248A (en) | 2021-09-03 | 2021-09-03 | Application of probiotic active peptide in preparation of medicine, food or health-care product with effect of preventing or treating diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113521248A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114621319A (en) * | 2021-12-22 | 2022-06-14 | 深圳科兴药业有限公司 | Probiotic active peptide, active peptide composition and application thereof in preparation of products with anti-inflammatory and/or antioxidant effects |
-
2021
- 2021-09-03 CN CN202111032263.7A patent/CN113521248A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114621319A (en) * | 2021-12-22 | 2022-06-14 | 深圳科兴药业有限公司 | Probiotic active peptide, active peptide composition and application thereof in preparation of products with anti-inflammatory and/or antioxidant effects |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100877600B1 (en) | Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis | |
| KR102204299B1 (en) | Therapeutic agent for coronavirus comprising Elaeocarpus sylvestris extract as effective component | |
| EP2070545A1 (en) | Oral compositions for the prevention and treatment of inflammatory disorders of the colon | |
| CN113521248A (en) | Application of probiotic active peptide in preparation of medicine, food or health-care product with effect of preventing or treating diarrhea | |
| WO2017159679A1 (en) | Polysaccharide digestion inhibitor | |
| AU2003204391B2 (en) | Composition and its therapeutic use | |
| WO2021248254A2 (en) | Pharmacotherapeutic doses of hesperidin or related bioflavonoids to adress infectious and/or inflammatory diseases | |
| JP5187935B2 (en) | Wound healing promoting composition containing Rahan fruit extract and application method | |
| EP4157326A1 (en) | Combination of active ingredients, compositions containing it and their use to sustain and strengthen the immune system | |
| EP2585056B1 (en) | Composition for treating lipid encapsulated virus infections | |
| JP7274725B2 (en) | therapeutic agent for chronic fatigue syndrome | |
| JP2003104901A (en) | Composition for health promotion | |
| KR20010009653A (en) | Composition for treating sexual dysfunction | |
| US11896611B1 (en) | Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation | |
| US11351148B1 (en) | Pharmaceutical composition Mix A to treat health conditions associated with elevated glucose levels | |
| RU2780346C1 (en) | Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract | |
| JP5484704B2 (en) | Fever symptom suppressant for the elderly | |
| RU2484842C2 (en) | Agent possessing general tonic, adaptogenic and immunity decrease preventing action, and method for preparing it | |
| CN111228247A (en) | Medicine containing benzylidene acetone for treating echinococcosis and preparation method thereof | |
| WO2021191928A1 (en) | Eflornithine composition and dosage forms for the treatment of viral infection | |
| CN104739854B (en) | NAC and chitosan Compound mouthwash | |
| WO2021224659A1 (en) | Pharmaceutical composition and kit-of-parts for use against infections caused by coronaviruses | |
| KR20230016199A (en) | Compositions and methods of treatment comprising glutathione | |
| US20210379117A1 (en) | Methods for alleviating post-polio muscle weakness and conditions similar thereto | |
| KR20220136909A (en) | Oral nanoparticle of bioactive substances and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |